Search results
Showing 1 to 15 of 47 results for alzheimer's disease
Dementia: assessment, management and support for people living with dementia and their carers (NG97)
This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)
Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.
View recommendations for TA217Show all sections
In development [GID-TA11220] Expected publication date: 23 July 2025
We are listening to your views on this Technology appraisal guidance. Comments close 27 March 2025.
In development [GID-TA11221] Expected publication date: 23 July 2025
We are listening to your views on this Technology appraisal guidance. Comments close 27 March 2025.
In development [GID-TA11379] Expected publication date: TBC
Our forward view highlights the areas we will prioritise in the coming year.
Musculoskeletal conditions account for one of the highest burdens of disease in England, with impacts on health-related quality of...
Gantenerumab for treating early Alzheimer's disease [TSID10668]
Awaiting development [GID-TA11072] Expected publication date: TBC
This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.
NICE's impact on preventing or delaying the onset of dementia
NICE's impact on preventing or delaying the onset of dementia
the impact of treating Alzheimer's disease on mortality and institutionalisation, and to assess the relationship between...